The European Medicines Agency has announced the withdrawal of marketing authorization for Vaxzevria, a coronavirus vaccine developed in partnership with the University of Oxford and AstraZeneca. The decision was made due to declining demand for the vaccine, which has not generated revenue since April 2023. This decline in demand is attributed to the surplus of new Covid-19 vaccines available, prompting AstraZeneca to cease manufacturing and supplying the product.

AstraZeneca has stated that they have initiated the withdrawal of marketing authorizations for Vaxzevria within Europe. Despite this, the company remains proud of the role the vaccine played in the global effort to end the pandemic. They are committed to working with regulators in other countries to determine the best course of action for its commercial future. This is a developing story and updates will be provided as more information becomes available.